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randomised controlled trials are required to inform these 
conclusions.
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RISK FOR OSTEOPOROTIC FRACTURES IS REDUCED IN
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OBJECTIVE: This study aimed to investigate the effect of per-
sistent bisphosphonate usage on the risk for hospitalization due
to osteoporotic fractures. METHODS: The PHARMO database,
which includes linked drug-dispensing records and hospital dis-
charge records of more than one million subjects in deﬁned areas
in The Netherlands, was used to identify new female users of
alendronate, etidronate or risedronate >50 years in the period
January 1996–January 2003. Persistence with bisphosphonate
treatment was determined using the method of Catalan. Within
the cohort a matched case control study was performed. Cases
were selected on the basis of a ﬁrst hospitalization for an osteo-
porotic fracture (index date). Controls were matched 10 :1 to
cases on month of inclusion in the cohort and were assigned a
random index date. The association with risk for fractures was
assessed for bisphosphonate use at the index date and for per-
sistent bisphosphonate use before the index date. RESULTS:
The study cohort included 8,845 new female bisphosphonate
users; 334 women (3.8%) were hospitalized for a fracture after
inclusion in the cohort. A total of 3,280 controls were matched
to the 334 cases. Bisphosphonate use at the index date signiﬁ-
cantly reduced the risk for osteoporotic fractures (RR 0.78;
95%CI 0.61–0.99, adjusted for age, previous fractures and co-
medication). At least one year of persistent bisphosphonate 
usage reduced the risk for osteoporotic fractures even more sub-
stantially (adjusted RR 0.70; 95%CI 0.50–0.99). CONCLU-
SIONS: These results emphasize the importance of persistent
bisphosphonate usage to obtain the maximal protective effect.
Previous studies have demonstrated that persistence with bis-
phosphonates is higher with less frequent dosing regimens but is
still suboptimal. This study has demonstrated that improving
persistence results in reduced hospitalization for osteoporotic
fractures.
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OBJCETIVE: Glucocorticoids are associated with increased frac-
ture risk. The balance between costs and effects of alendronate
on glucocorticoid-induced osteoporosis (GIOP) was compared to
alfacalcidol and no preventive treatment. METHODS: Cost-
effectiveness analysis with a Markov model to compare 
alendronate and alfacalcidol to placebo based on 5 years of treat-
ment. Lumbar spine bone mineral densities (BMD) of a double
blind randomized controlled trial in patients starting oral GCs
in a daily dosage of 7.5mg prednisone equivalent or higher were
used. Also pooled estimates of the relative risk (RR) of vertebral
fractures from literature were used to estimate fracture incidence.
A discounted iCER threshold of €30.000 per quality-adjusted
life-year (QALY) gained was assumed. RESULTS: Mean age was
60 years. With BMD the iCER in women treated with alen-
dronate was €94.261 per QALY gained an €144.000 in the alfa-
calcidol group. With the pooled RRs in women the iCER were
€58.and €63.115 respectively. Sensitivity analyses applying
pooled RRs to all types of fractures resulted in €29.389 and
€26.457 for women. For men neither treatment reached the
threshold. With BMD as predictor €30.000 was reached at €201
annual costs for alendronate in women and at €78 in men. For
alfacalcidol the threshold prices were €103 in women and €40
in men. With the pooled RRs the threshold price of alendronate
was €300 per year in women and €106 in men. For alfacalcidol
the prices were €218 in women and €72 in men. Sensitivity analy-
sis showed that with treatment duration of 1 year both treat-
ments became cost-effective, presuming persistent beneﬁcial
effect on bone after discontinuation of the drugs. CONCLU-
SIONS: Overall, alendronate and alfacalcidol do not appear
cost-effective in prevention of GIOP in patients with a mean age
of 60 years.
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OBJECTIVE: To assess the CE of risendronate vs. alendronate
in post-menopausal women with established osteoporosis.
METHODS: A fracture-incidence based Markov model was
used to perform CEA from a health-care payer perspective, based
on Polish data on health-care resource utilisation and unit cost.
The basic transition probabilities have been taken for published
epidemiological data, where possible from Poland. Efﬁcacy of
treatments in terms of ability to reduce the incidence of hip, ver-
tebral, wrist fractures was populated from the systematic review
and modeled by the use of relative risks in entering a transition
state. Treatments were given for 5 years, assuming that the effect
on fracture probability is instantaneous and persist unchanged
through the treatment period. Separately women at the ages 50,
60, 70, or 80 years of age were analysed. Costs and clinical out-
comes were observed from the time of therapy initiation until
the end of treatment. The effectiveness frontier was mapped and
the cost-effectiveness of each therapy was examined in terms 
of ICER. Extensive sensitivity analyses were undertaken.
RESULTS: At each age-group risendronate was the most effec-
tive and most costly option, giving 17.6; 11.8; 6.5 and 3.08
QALY at 7707.7, 7745.7, 7421.5, and 6117 PLN (1 EURO = 4
PLN) in 50, 60, 70, and 80 aged women, respectively. In the
group at 50 and 70 alendronate was excluded because of
extended dominance and the ICER for risendronate vs. no treat-
ment was 137,651 and 71,084 PLN/QALY, respectively. The
ICER for risendronate vs. alendronate in women at 60 and 80
was 267,393 and 46,732 PLN/QALY, respectively. These ﬁnd-
ings were fairly insensitive to variation in the main parameters.
CONCLUSION: Considering the suggested threshold for cost-
effectiveness, calculated on the basis of 1-year haemodialysis
treatment cost (64,000 PLN) risendronate in comparison to alen-
dronate appears to be cost-effective option in women at 70 and
80.
